Loading... Please wait...
About Us
Contact Us
Privacy Policy
Sign in
or
Create an account
My Account
View Basket
Checkout
Search
Home
Latest Reports
Browse by
Biosimilar Index
Dossier
FirstView
FirstView NPS+
FirstWord Pharma
Therapy Trends
Therapy Trends Updates
Latest Reports
Therapy Area Reports
Report Subject
Emerging Markets
Generics/Biosimilars
Market Access
Medical Affairs
Pharma Marketing
Pharma Sales
Technology/Digital Health
Orphan Drugs
Sort by:
Featured Items
Newest Items
Bestselling
Alphabetical: A to Z
Alphabetical: Z to A
« Previous
Next »
Pages:
1
2
3
4
5
6
7
8
9
10
Learn More
Medical Affairs Reputations: Cancer Pain (US) 2017
Disappointing scores show that medical affairs teams need to up their game The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a lacklustre performance in the past 6 months...
Compare
Learn More
The Future of Biosimilars in Europe
Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...
Compare
Learn More
Ulcerative Colitis: Update Bulletin [June 2017]
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on: Takeda announcing the presentation of real-world...
Compare
Learn More
Market Access Impact: Asthma/COPD (EU5) 2017
Market barriers cost most brands share, but awareness is a bigger issue for some In the EU5 countries, market barriers affect a modest 15% of asthma/COPD prescriptions, but they’re siphoning market share from most...
Compare
Learn More
Market Access Impact: Parkinson's Disease (EU5) 2017
Is patient preference costing your brand market share? Market barriers affect nearly 15% of Parkinson’s disease prescriptions in the EU5 countries, causing half of the 8 brands we surveyed to lose market share...
Compare
Learn More
Market Access Impact: Asthma/COPD (US) 2017
Two brands enjoy big market share boosts as market barriers hinder competitors Market barriers affect more than a third of asthma/COPD prescriptions in the US. According to our survey, roughly 55% of doctors...
Compare
Learn More
Market Access Impact: Parkinson's Disease (US) 2017
Are high cost and market access problems costing your brand market share? Are market barriers holding your brand back? According to our survey of US-based neurologists, 8 of the 11 Parkinson’s disease treatments...
Compare
Learn More
Type 2 Diabetes Mellitus KOL Insight : Update Bulletin [June 2017]
This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca’s announcement of positive top-line results from the Phase...
Compare
Learn More
Market Access Impact: Chronic Lymphocytic Leukaemia (CLL) EU5 2017
How are market barriers moving the goalposts for CLL drugs in Europe? Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in Europe? One drug is clearly popular and others are playing...
Compare
Learn More
Market Access Impact: Haemophilia B (EU5)
Leading brands have room to grow At least 30% of the haematologists we surveyed don’t prescribe the 7 leading haemophilia B treatments we asked them about. But most are willing to consider them, so there’s...
Compare
Learn More
Market Access Impact: Haemophilia B (US)
Leading brands have room to grow At least 30% of the haematologists we surveyed don’t prescribe the 7 leading haemophilia B treatments we asked them about. But most are willing to consider them, so there’s...
Compare
Learn More
Market Access Impact: Chronic Lymphocytic Leukaemia (CLL) US 2017
How are market barriers moving the goalposts for CLL drugs in the US? Just how significantly are market barriers skewing prescribing behaviour for CLL drugs in the US? One drug is clearly popular and others are playing...
Compare
Learn More
Market Access Impact: Haemophilia A (EU5) 2017
Losing share to competitors? Understanding market barriers can help close the gap Haemophilia A treatment is a highly competitive market in the EU5 countries, where market shares for several of the brands we surveyed...
Compare
Learn More
Market Access Impact: Haemophilia A (US) 2017
Losing share to competitors? Understanding market barriers can help close the gap Haemophilia A treatment is a highly competitive market in the US, where half of the 8 brands we surveyed have nearly equal market share...
Compare
Learn More
NPS+ Growth Hormone Deficiency (US) 2017
Why are some US GHD brands standing out more than others? There are various options available to US endocrinologists to treat growth hormone deficiency (GHD). Clearly some of these options are achieving greater...
Compare
Learn More
NPS+ Melanoma (EU5) 2017
Leading melanoma treatments may have a differentiation problem Two melanoma treatments are comfortably ahead of the pack in the EU5, earning by far the highest satisfaction scores from medical oncologists. Can either...
Compare
« Previous
Next »
Pages:
1
2
3
4
5
6
7
8
9
10
About Us
Contact Us
Privacy Policy
customer.service@firstwordpharma.com
All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved